Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breo

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

- PMLiVE

GSK and AZ drugs impress in lupus trials

Raises hope for better treatment for debilitating disease

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

Teva Pharma logo

TEVA buys Mexico’s RIMSA for $2.3bn

Follows acquisition ofAllergan’s generic drugs business

- PMLiVE

IBM teams up with Teva for global eHealth collaboration

Willalso partner with ICON on cancer trials project

- PMLiVE

GSK’s Breo fails to show survival benefit in COPD

Comes as GSK sees continued slump in sales

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

- PMLiVE

Gilead and GSK pulmonary hypertension drugs work in tandem

Letairis and Adcirca combined shows clear therapeutic benefit

Teva Pharma logo

Teva takes controlling stake in genomics specialist

World’s largest generics firm takes deeper steps into patented medicines development

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links